ATE271040T1 - Substituierte pyridinderivate, deren herstellung und deren verwendung als modulatoren von acetylcholin-rezeptoren - Google Patents

Substituierte pyridinderivate, deren herstellung und deren verwendung als modulatoren von acetylcholin-rezeptoren

Info

Publication number: ATE271040T1
Authority: AT; Austria
Prior art keywords: disorders; disease; modulators; acetylcholine receptors; compounds
Prior art date: 1995-04-07

Application number

AT96913789T

Other languages

English (en)

Inventor

Nicholas D Cosford

Jean-Michel Vernier

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-07

Filing date

1996-04-04

Publication date

2004-07-15

1996-04-04 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2004-07-15 Application granted granted Critical

2004-07-15 Publication of ATE271040T1 publication Critical patent/ATE271040T1/de

Links

108010009685 Cholinergic Receptors Proteins 0.000 title abstract 4
102000034337 acetylcholine receptors Human genes 0.000 title abstract 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
208000035475 disorder Diseases 0.000 abstract 5
206010012289 Dementia Diseases 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
208000030507 AIDS Diseases 0.000 abstract 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000000044 Amnesia Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
208000032841 Bulimia Diseases 0.000 abstract 1
206010006550 Bulimia nervosa Diseases 0.000 abstract 1
206010010774 Constipation Diseases 0.000 abstract 1
206010012735 Diarrhoea Diseases 0.000 abstract 1
208000027534 Emotional disease Diseases 0.000 abstract 1
201000004311 Gilles de la Tourette syndrome Diseases 0.000 abstract 1
208000023105 Huntington disease Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
208000026139 Memory disease Diseases 0.000 abstract 1
208000019022 Mood disease Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
208000028017 Psychotic disease Diseases 0.000 abstract 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
206010043118 Tardive Dyskinesia Diseases 0.000 abstract 1
208000000323 Tourette Syndrome Diseases 0.000 abstract 1
208000016620 Tourette disease Diseases 0.000 abstract 1
208000025865 Ulcer Diseases 0.000 abstract 1
206010048010 Withdrawal syndrome Diseases 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
230000003281 allosteric effect Effects 0.000 abstract 1
208000022531 anorexia Diseases 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
230000006793 arrhythmia Effects 0.000 abstract 1
206010003119 arrhythmia Diseases 0.000 abstract 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
230000002567 autonomic effect Effects 0.000 abstract 1
210000002318 cardia Anatomy 0.000 abstract 1
230000004706 cardiovascular dysfunction Effects 0.000 abstract 1
206010061428 decreased appetite Diseases 0.000 abstract 1
230000004064 dysfunction Effects 0.000 abstract 1
230000008482 dysregulation Effects 0.000 abstract 1
230000037406 food intake Effects 0.000 abstract 1
235000012631 food intake Nutrition 0.000 abstract 1
230000027119 gastric acid secretion Effects 0.000 abstract 1
230000007661 gastrointestinal function Effects 0.000 abstract 1
230000005176 gastrointestinal motility Effects 0.000 abstract 1
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
230000006984 memory degeneration Effects 0.000 abstract 1
208000023060 memory loss Diseases 0.000 abstract 1
230000036651 mood Effects 0.000 abstract 1
230000007659 motor function Effects 0.000 abstract 1
208000015706 neuroendocrine disease Diseases 0.000 abstract 1
239000004031 partial agonist Substances 0.000 abstract 1
208000028591 pheochromocytoma Diseases 0.000 abstract 1
150000003222 pyridines Chemical class 0.000 abstract 1
230000020341 sensory perception of pain Effects 0.000 abstract 1
201000009032 substance abuse Diseases 0.000 abstract 1
231100000736 substance abuse Toxicity 0.000 abstract 1
208000011117 substance-related disease Diseases 0.000 abstract 1
238000006467 substitution reaction Methods 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
231100000397 ulcer Toxicity 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT96913789T 1995-04-07 1996-04-04 Substituierte pyridinderivate, deren herstellung und deren verwendung als modulatoren von acetylcholin-rezeptoren ATE271040T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/419,597 US5585388A (en)	1995-04-07	1995-04-07	Substituted pyridines useful as modulators of acetylcholine receptors
PCT/US1996/005078 WO1996031475A2 (en)	1995-04-07	1996-04-04	Substituted pyridine derivatives, their preparation and their use as modulators of acetylcholine receptors

Publications (1)

Publication Number	Publication Date
ATE271040T1 true ATE271040T1 (de)	2004-07-15

Family

ID=23662934

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96913789T ATE271040T1 (de)	1995-04-07	1996-04-04	Substituierte pyridinderivate, deren herstellung und deren verwendung als modulatoren von acetylcholin-rezeptoren

Country Status (9)

Country	Link
US (3)	US5585388A (de)
EP (1)	EP0871615B1 (de)
JP (1)	JP4138872B2 (de)
AT (1)	ATE271040T1 (de)
AU (1)	AU718517B2 (de)
CA (1)	CA2217651A1 (de)
DE (1)	DE69632916T2 (de)
ES (1)	ES2224167T3 (de)
WO (1)	WO1996031475A2 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6562629B1 (en)	1999-08-11	2003-05-13	Cedars-Sinai Medical Center	Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US7048906B2 (en)	1995-05-17	2006-05-23	Cedars-Sinai Medical Center	Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) *	1999-08-11	2005-03-01	Cedars-Sinai Medical Center	Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6979695B2 (en)	1996-04-23	2005-12-27	Targacept, Inc.	Compounds capable of activating cholinergic receptors
US20020052497A1 (en) *	2000-03-09	2002-05-02	Targacept, Inc.	Compounds capable of activating cholinergic receptors
US6437138B1 (en)	1996-06-06	2002-08-20	Abbott Laboratories	3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6133253A (en) *	1996-12-10	2000-10-17	Abbott Laboratories	3-Pyridyl enantiomers and their use as analgesics
IL130083A0 (en) *	1996-12-10	2000-02-29	Abbott Lab	3-Pyridyl enantiomers and their use as analgesics
US5811442A (en) *	1997-02-21	1998-09-22	Bencherif; Merouane	Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US5861423A (en)	1997-02-21	1999-01-19	Caldwell; William Scott	Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US6531606B1 (en)	1997-02-21	2003-03-11	Targacept, Inc.	Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
WO1998053820A1 (en)	1997-05-29	1998-12-03	H. Lundbeck A/S	Treatment of schizophrenia and psychosis
US7214686B2 (en)	1997-06-30	2007-05-08	Targacept, Inc.	Pharmaceutical compositions and methods for effecting dopamine release
US6362009B1 (en)	1997-11-21	2002-03-26	Merck & Co., Inc.	Solid phase synthesis of heterocycles
EP1068186A2 (de)	1998-04-02	2001-01-17	Targacept, Inc.	3-pyridylalkoxyamine oder aryloxyalkylamine derivate als cholinergische agonisten
MXPA00009634A (es) *	1998-04-02	2005-06-20	Targacept Inc	Derivados de azatriciclo[3.3.1.1]decano y composiciones farmaceuticas que los contienen.
US7790757B2 (en) *	1998-06-16	2010-09-07	Targacept, Inc.	Compounds capable of activating cholinergic receptors
KR100593433B1 (ko) *	1998-06-16	2006-06-28	타가셉트 인코포레이티드	아릴 치환된 올레핀계 아민 및 콜린성 수용체 작용제로서의 그들의 용도
US6232316B1 (en)	1998-06-16	2001-05-15	Targacept, Inc.	Methods for treatment of CNS disorders
US20050131034A1 (en) *	1998-06-16	2005-06-16	Caldwell William S.	Compounds capable of activating cholinergic receptors
US6232326B1 (en)	1998-07-14	2001-05-15	Jodi A. Nelson	Treatment for schizophrenia and other dopamine system dysfunctions
US6218383B1 (en)	1998-08-07	2001-04-17	Targacept, Inc.	Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
KR100713572B1 (ko) *	1999-05-21	2007-05-02	아보트 러보러터리즈	중추 신경계 제제로서 유용한 헤테로사이클릭 치환된 아미노아자사이클 및 이를 포함하는 약제학적 조성물
US6833370B1 (en)	1999-05-21	2004-12-21	Abbott Laboratories	Heterocycle substituted aminoazacycles useful as central nervous system agents
BR0007229A (pt) *	1999-05-21	2002-09-10	Abbott Lab	Aminoazaciclos heterocìclicos substituìdos úteis como agentes de sistema nervoso central
US20010031771A1 (en)	1999-05-24	2001-10-18	Gary Maurice Dull	Pharmaceutical compositions and methods for use
WO2000075110A1 (en) *	1999-06-07	2000-12-14	Targacept, Inc.	Pharmaceutical compositions and methods for use
DE10005150A1 (de) *	2000-02-07	2001-08-09	Merck Patent Gmbh	Verfahren zur Herstellung von 5-Arylnicotinaldehyden
US6809105B2 (en)	2000-04-27	2004-10-26	Abbott Laboratories	Diazabicyclic central nervous system active agents
MY145722A (en)	2000-04-27	2012-03-30	Abbott Lab	Diazabicyclic central nervous system active agents
US6458804B1 (en)	2001-01-26	2002-10-01	R.T. Alamo Venturesi, Llc	Methods for the treatment of central nervous system disorders in certain patient groups
SI1427724T1 (sl) *	2001-09-19	2006-10-31	Merck Patent Gmbh	Nova uporaba substituiranih aminometil-kromanov
JP2005538683A (ja)	2001-12-14	2005-12-22	ターガセプト，インコーポレイテッド	中枢神経系疾患の治療のための方法及び組成物
US7091357B2 (en) *	2001-12-26	2006-08-15	University Of Kentucky Research Foundation	Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
MXPA03000145A (es)	2002-01-07	2003-07-15	Pfizer	Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
GB0211230D0 (en)	2002-05-16	2002-06-26	Medinnova Sf	Treatment of heart failure
US6908935B2 (en)	2002-05-23	2005-06-21	Amgen Inc.	Calcium receptor modulating agents
US7176322B2 (en)	2002-05-23	2007-02-13	Amgen Inc.	Calcium receptor modulating agents
EA009789B1 (ru)	2002-07-05	2008-04-28	Таргасепт, Инк.	N-арилдиазаспирациклические соединения и способы их получения и применения
AU2003254016A1 (en)	2002-07-19	2004-02-09	Catholic Healthcare West	Methods and compositions relating to chimeric nicotinic receptor subunits
US7098331B2 (en) *	2003-03-05	2006-08-29	Targacept, Inc.	Arylvinylazacycloalkane compounds and methods of preparation and use thereof
CA2522431A1 (en) *	2003-04-24	2004-11-11	Merck & Co., Inc.	Inhibitors of akt activity
CA2522435C (en) *	2003-04-24	2011-04-12	Merck & Co., Inc.	Inhibitors of akt activity
SI1678172T1 (sl)	2003-10-15	2010-04-30	Targacept Inc	AzabicikliŽŤne spojine za lajĹˇanje boleŽŤine in zdravljenje motenj centralnega ĹľivŽŤnega sistema
ES2330849T3 (es) *	2004-04-02	2009-12-16	Arterial Remodelling Technologies Inc.	Ensamblaje de stent basado en polimero.
BRPI0512046A (pt)	2004-06-15	2008-02-06	Pfizer	derivados de ácido benzimidazolona carboxìlico
US7737163B2 (en)	2004-06-15	2010-06-15	Pfizer Inc.	Benzimidazolone carboxylic acid derivatives
MX2007000885A (es)	2004-07-23	2007-03-12	Pfizer	Derivados de piridina.
WO2006034089A1 (en)	2004-09-20	2006-03-30	Targacept, Inc.	Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity
US7459469B2 (en)	2004-11-10	2008-12-02	Targacept, Inc.	Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru)	2004-11-10	2009-11-25	Таргасепт, Інк.	Гидроксибензоатные соли метаникотиновых соединений
US20090088433A1 (en)	2005-01-26	2009-04-02	Bertrand Leblond	Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
MX2007011105A (es)	2005-03-10	2007-10-08	Pfizer	Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
NZ565628A (en)	2005-08-22	2011-03-31	Targacept Inc	Heteroaryl-substituted diazatricycloalkanes, methods for its preparation and use thereof
TWI389889B (zh)	2006-05-09	2013-03-21	Targacept Inc	（２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2357174A1 (de)	2006-05-09	2011-08-17	AstraZeneca AB	Salzformen von (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-Penten-2-Amin
TWI454262B (zh)	2006-11-02	2014-10-01	Targacept Inc	菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
ATE509925T1 (de)	2006-11-17	2011-06-15	Pfizer	Substituierte bicyclocarbonsäureamidverbindungen
EP2112923A1 (de)	2007-01-22	2009-11-04	Targacept Inc.	Intranasale, orale und sublinguale verabreichung von metanikotin-analogen
TW200845977A (en)	2007-03-30	2008-12-01	Targacept Inc	Sub-type selective azabicycloalkane derivatives
SA08290475B1 (ar)	2007-08-02	2013-06-22	Targacept Inc	(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
DE602008005928D1 (de)	2007-10-01	2011-05-12	Comentis Inc	1h-indol-3-carbonsäure-chinuclidin-4-ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit
AR072899A1 (es)	2008-08-07	2010-09-29	Merck Sharp & Dohme	Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
MX2011004551A (es) *	2008-10-30	2011-05-25	Merck Sharp & Dohme	Antagonistas del receptor de orexina de isonicotinamida.
TW201024283A (en)	2008-12-01	2010-07-01	Targacept Inc	Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
HUE050540T2 (hu)	2008-12-01	2020-12-28	Oyster Point Pharma Inc	(R)-5-((E)-2-pirrolidin-3-ilvinil)pirimidin elõállítása és új sóformái
US9145396B2 (en)	2008-12-01	2015-09-29	Targacept, Inc.	Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
WO2010080757A2 (en)	2009-01-07	2010-07-15	Astrazeneca Ab	Combinations with an alpha-4beta-2 nicotinic agonist
TW201031664A (en)	2009-01-26	2010-09-01	Targacept Inc	Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
KR101338555B1 (ko)	2009-05-15	2013-12-09	노파르티스 아게	알도스테론 신타제 억제제로서의 아릴 피리딘
KR20120120190A (ko)	2009-12-07	2012-11-01	타가셉트 인코포레이티드	신경원성 니코틴 아세틸콜린 수용체 리간드인 ３，６?디아자비시클로［３．１．１］헵탄
KR20130081221A (ko)	2010-05-20	2013-07-16	아스트라제네카 아베	아릴 치환된 올레핀계 아민의 신규 제조 방법
CA2799203C (en)	2010-05-27	2018-05-08	Targacept, Inc.	Nicotinic receptor non-competitive antagonists
WO2012125518A1 (en)	2011-03-14	2012-09-20	Targacept, Inc.	Salt forms of 3 - cyclopropylcarbonyl - 3, 6 - diazabicyclo [3.1.1] heptane
WO2012129262A1 (en)	2011-03-23	2012-09-27	Targacept, Inc.	Treatment of attention deficit/hyperactivity disease
TW201311698A (zh)	2011-08-22	2013-03-16	Targacept Inc	作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
EP3166940A4 (de)	2014-07-11	2018-04-25	Alpharmagen, LLC	Chinuclidinverbindungen zur modulierung der aktivität des alpha7-nikotinischen acetylcholinrezeptors
US9724340B2 (en)	2015-07-31	2017-08-08	Attenua, Inc.	Antitussive compositions and methods
EP3684357B1 (de) *	2017-09-19	2022-12-28	Merck Sharp & Dohme LLC	Allosterische heteroarylmodulatoren von nikotinischen acetylcholinrezeptoren
CN119775199B (zh) *	2025-02-21	2025-08-01	澳门科技大学	一种抗炎小分子化合物及其合成方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2194567A (en) *	1938-02-28	1940-03-26	Pyridium Corp	Esters of aminopyridine carboxylic acid and processes for producing the same
GB945824A (en) *	1960-09-02	1964-01-08	Merck Ag E	ªÏ-(pyridyl-3)-or ªÏ-(piperidyl-3)-propanol and derivatives thereof and processes for their manufacture
DE1231704B (de) *	1963-12-19	1967-01-05	Josef Klosa Dipl Chem Dr Rer N	Verfahren zur Herstellung neuer Diaryl-alkylaminoverbindungen mit heterocyclischen Ringen
NL6401902A (de) *	1964-02-27	1965-08-30
US3313822A (en) *	1965-07-14	1967-04-11	Warner Lambert Pharmaceutical	Diphenyl substituted aminoalkyl pyridines
SE361663B (de) *	1971-04-28	1973-11-12	Haessle Ab
LU65414A1 (de) *	1972-05-24	1973-12-04
FR2187317B2 (de) *	1972-06-07	1975-06-20	Hexachimie
US4009174A (en) *	1972-12-08	1977-02-22	The Boots Company Limited	Esters of substituted nicotinic acids
DE2364685C3 (de) *	1973-12-27	1978-06-15	Beiersdorf Ag, 2000 Hamburg	Phenoxyäthylamine
GB1485919A (en) *	1975-08-12	1977-09-14	Grindstedvaerket As	Pyridine derivatives
FR2341311A1 (fr) *	1976-02-20	1977-09-16	Parcor	Derives de la pyridoxine
JPS52125170A (en) *	1976-04-12	1977-10-20	Yoshitomi Pharmaceut Ind Ltd	Pyridine derivatives
US4444774A (en) *	1982-07-29	1984-04-24	American Cyanamid Company	7-Heteroaryl[1,2,4]triazolo[1,5-a]pyrimidines
IL100688A (en) *	1987-08-01	1995-08-31	Takeda Chemical Industries Ltd	Intermediates for the production of unsaturated amines in position A and the process for their preparation
IT1231477B (it) *	1989-07-12	1991-12-07	Sigma Tau Ind Farmaceuti	(pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
CA2029497C (en) *	1989-11-08	2002-06-04	Kunihiro Ninomiya (Deceased)	4-acylaminopyridine derivative
US5418229A (en) *	1990-01-06	1995-05-23	Alker; David	Muscarinic receptor antagonists
DE4038335A1 (de) *	1990-12-01	1992-06-04	Boehringer Mannheim Gmbh	Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel
US5212188A (en) *	1992-03-02	1993-05-18	R. J. Reynolds Tabacco Company	Method for treatment of neurodegenerative diseases
US5214060A (en) *	1992-04-10	1993-05-25	R. J. Reynolds Tobacco Company	Method for treatment of neurodegenerative diseases
US5232932A (en) *	1992-05-21	1993-08-03	R. J. Reynolds Tobacco Company	Method for treatment of neurodegenerative diseases
DE4232561A1 (de) *	1992-09-29	1994-03-31	Bayer Ag	Bekämpfung von Fischparasiten
IL107184A (en) *	1992-10-09	1997-08-14	Abbott Lab	Heterocyclic ether compounds that enhance cognitive function
EP0637237B1 (de) *	1993-02-23	2004-05-19	Brigham And Women's Hospital, Inc.	Calciumrezeptoraktive moleküle

1995
- 1995-04-07 US US08/419,597 patent/US5585388A/en not_active Expired - Lifetime
- 1995-06-07 US US08/480,405 patent/US5686473A/en not_active Expired - Fee Related
- 1995-06-07 US US08/488,122 patent/US5736560A/en not_active Expired - Fee Related
1996
- 1996-04-04 JP JP53054896A patent/JP4138872B2/ja not_active Expired - Fee Related
- 1996-04-04 AT AT96913789T patent/ATE271040T1/de not_active IP Right Cessation
- 1996-04-04 CA CA002217651A patent/CA2217651A1/en not_active Abandoned
- 1996-04-04 DE DE69632916T patent/DE69632916T2/de not_active Expired - Fee Related
- 1996-04-04 AU AU56636/96A patent/AU718517B2/en not_active Ceased
- 1996-04-04 ES ES96913789T patent/ES2224167T3/es not_active Expired - Lifetime
- 1996-04-04 WO PCT/US1996/005078 patent/WO1996031475A2/en not_active Ceased
- 1996-04-04 EP EP96913789A patent/EP0871615B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0871615A1 (de)	1998-10-21
US5585388A (en)	1996-12-17
DE69632916T2 (de)	2005-07-14
CA2217651A1 (en)	1996-10-10
WO1996031475A3 (en)	1997-02-06
EP0871615B1 (de)	2004-07-14
ES2224167T3 (es)	2005-03-01
WO1996031475A2 (en)	1996-10-10
JPH11503430A (ja)	1999-03-26
DE69632916D1 (de)	2004-08-19
US5686473A (en)	1997-11-11
JP4138872B2 (ja)	2008-08-27
US5736560A (en)	1998-04-07
AU5663696A (en)	1996-10-23
AU718517B2 (en)	2000-04-13

Legal Events

Date	Code	Title	Description
2005-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69632916D1 (de)	2004-08-19	Substituierte Pyridinderivate, deren Herstellung und deren Verwendung als Modulatoren von Acetylcholin-Rezeptoren
ATE248160T1 (de)	2003-09-15	Pyridin acetylcholin-rezeptor-modulatoren
ATE240942T1 (de)	2003-06-15	Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren
DE69528823D1 (en)	2002-12-19	Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten
MX9706969A (es)	1997-11-29	3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
NO940927L (no)	1994-03-15	Kondenserte tricykliske nitrogenholdige heterocykler som substans-P-reseptor-antagonister
NO963785L (no)	1996-11-01	Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser
AU1856397A (en)	1997-08-22	Heterocyclic derivatives as antidiabetic and antiobesity agents
TR199801255T2 (xx)	1998-10-21	Vitronektin resept�r antagonistleri.
RU94046364A (ru)	1996-10-10	Замещенные гетероциклы, способ их получения, фармокомпозиция, способ лечения
DE69737683D1 (de)	2007-06-14	Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
EP0835869A3 (de)	1998-05-06	Serotonin-5-HT1F-Rezeptor Agoniste
DE60135029D1 (de)	2008-09-04	Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
MY115164A (en)	2003-04-30	Morpholine and thiomorpholine tachykinin receptor antagonists
DK0946189T3 (da)	2002-12-16	Anvendelse af aktivatorer af CNTF (ciliær neurotrofisk faktor) receptor til behandling af adipositas
DE69232309D1 (de)	2002-01-31	Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen
SE1267869T3 (de)	2004-08-31
DE69333108D1 (de)	2003-08-28	Benzodiazepin derivate verwendbar als cck-rezeptoren antagonisten
TR200100462T2 (tr)	2001-09-21	Muskarinik agonistleri ve antagonistleri
NO961333L (no)	1996-04-01	Nye pyrazolderivater som angiotensin-II-antagonister
PL297472A1 (en)	1994-01-24	Benzimidazoles, therapeutic agents containing such compounds and method of obtaining them
DE69013871D1 (de)	1994-12-08	4-Benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.
CA2336009A1 (en)	1999-12-29	Use of receptors of the rev-erb family to screen substances which are useful in the treatment of lipid metabolism dysfunctions
ATE43610T1 (de)	1989-06-15	Acino-foetale differenzierungsproteine verbunden mit krebs des pankreas, antiserum und monoklonale antikoerper gegen diese proteine und verfahren zu ihrer herstellung.
DE59103032D1 (de)	1994-10-27	Pulverlacke und die Verwendung von ausgewählten Bindemittelkombinationen für Pulverlacke.